AMERSFOORT & BREDA, the Netherlands--()--APO-T B.V. and LinXis B.V., both privately owned oncology companies, announced today that LinXis has granted APO-T an exclusive worldwide license for the development and commercialization of fully-human antibody-drug-conjugates using APO-T’s MAGE-HLA targeted antibodies and LinXis’ unique LX linker technology. In exchange, LinXis will receive milestone payments and royalties.
“We are excited to license this program from LinXis, a company known for the development of innovative linker technology for the conjugation of cytotoxic drugs to antibodies. We are convinced by the sound scientific data LinXis has built around its linker program and we believe it to be a valuable addition to our proprietary oncology pipeline. The in-licensing strengthens the company’s development pipeline and its intellectual property base”, said Johan Renes, CEO of APO-T.
Dr. HendrikJan Houthoff, LinXis’ Head of Research, commented "APO-T’s molecule portfolio targeting MAGE-HLA has demonstrated considerable promise in preclinical studies, and we look forward to working with APO-T. There is a strong medical need for highly specific and efficacious tumor-targeting treatments and, with the combination of APO-T’s tumor-specific antibodies and our unique linker technology (LX), we are now well suited to develop first in class novel therapeutics highly beneficial to cancer patients.”
APO-T is a biopharmaceutical company focused on the development and commercialization of proprietary biotherapeutics for oncology. APO-T has developed fully-human antibodies and antibody fragments that target any tumor cell that expresses a MAGE-A peptide in the context of MHC-1. Many different kinds of tumors expose this MAGE-MHC-1 peptide complex. They are suitable targets for the specific delivery of a toxic effect inside tumor cells, leaving healthy cells essentially unaffected. The biomolecules allow effective treatment of cancer patients (including immuno-compromised patients) and prevent or delay escape of tumor cells from treatment.
LinXis is a biotechnology company dedicated to the discovery and development of proprietary methods to effectively link drugs (e.g. cytotoxic drugs, kinase inhibitors) to targeting moieties such as antibodies, by using (transition-)metal ion complexes without affecting the immunoreactivity of the antibody. LinXis collaborates with the Utrecht Institute of Pharmaceutical Sciences and the VU Medical Centre Amsterdam.